Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients

Metastatic clear-cell renal cell carcinoma (ccRCC) is sensitive to therapy with lenvatinib and pembrolizumab. The CLEAR trial demonstrated positive outcomes even in patients with a low tumor burden. In a subset of patients with metastatic ccRCC, the presence of a low tumor burden suggests that incorporating stereotactic body radiotherapy (SBRT) into systemic therapy could be a strategy to enhance the anti-tumor response, while maintaining an acceptable toxicity profile. This study evaluates the contribution of SBRT in a subgroup of patients who have achieved stable disease while receiving lenv

Trial Details

NCT ID
NCT07928167
Phase
PHASE2
Sponsor
Kidney Cancer Research Bureau
Status
RECRUITING
Cancer Type
Clear Cell Renal Cell Carcinoma Kidney Cancer
Interventions
  • Lenvatinib
  • Pembrolizumab
  • Stereotactic Body Radiation Therapy (SBRT)
Locations (sample)
  • Kazan', Russia|55.78874,49.12214
  • Moscow, Russia|55.75204,37.61781
  • Moscow, Russia|55.75204,37.61781
  • Orenburg, Russia|51.76712,55.09883
  • Saint Petersburg, Russia|59.93863,30.31413

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Histologically confirmed clear-cell renal cell carcinoma.
  • Presence of measurable lesions per RECIST 1.1.
  • Sum of diameters of target lesions ≤ 7 cm.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Clear Cell Renal Cell Carcinoma Kidney Cancer Trials on Trialify →